Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has claimed millions of lives globally to date. Rapid accumulation of co-occurring mutations has led to the emergence of viral variants which appear to be more transmissible, virulent, or both. Variants of concern (VOC) now include those belonging to the B.1.1.7, B.1.351, and P.1 lineages. Early detection of VOC and the ability to retrospectively follow their respective, longitudinal prevalence in communities is wanting. Wastewater-based epidemiology (WBE) allows tracking of disease prevalence in the general population using RT-qPCR to detect viral fragments, but ongoing longitudinal studies have yet to differentiate between these variants. Here, we describe and validate a primer extension strategy to amplify and distinguish B.1.1.7-specific, from non-B.1.1.7 alleles by combining new forward, and existing CDC 2019-nCoV_N1 qPCR probes and reverse primers. This assay can be quickly implemented within a current SARS-CoV-2 WBE framework with minimal cost with the goal of providing early detection of increasing B.1.1.7 transmission in a community prior to identification through clinical testing and confirmation via secondary screening strategies. As such, this assay can provide public health units with an additional and much needed metric to be able to rapidly triangulate B.1.1.7 prevalence.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by a CHEO (Children's Hospital of Eastern Ontario) CHAMO (Children's Hospital Academic Medical Organization) grant, awarded to Dr. Alex E. MacKenzie.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The patient specimen used in this study was anonymous and its use was approved by the Ottawa Health Science Network Research Ethics Board (OHSN-REB) under REB 20200235-01H.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
